• Premier League Partnership Extended with 60% Increase in Contract Value
• Chris Davis Appointed as Chief Marketing Officer to Drive Global Growth
• Additional $3 Million Secured Through Convertible Note Facility

HITIQ Limited (ASX: HIQ), a global leader in concussion management technologies, achieved significant milestones during the December 2024 quarter, reflecting its ongoing growth trajectory and commitment to delivering world-class solutions in the health and performance sector. The period was marked by a landmark extension of the Company's partnership with the Premier League, alongside a strategic leadership appointment aimed at driving HITIQ's global ambitions and securing an additional $3 million in funding. HITIQ reinforced its position as a trusted technology provider in elite sports with the extension of its agreement with the Premier League for an additional 18 months. The new contract represents a 60% increase in annual contract value compared to the previous agreement, underlining the growing recognition of HITIQ's innovative concussion management solutions. The Premier League's decision to continue this partnership signals confidence in the effectiveness of HITIQ's CSX Concussion Assessment Technology, which remains integral to the league's commitment to player safety. During the quarter, HITIQ appointed Chris Davis as Chief Marketing Officer, a move aimed at driving the Company's global marketing and customer engagement strategy. Mr. Davis's appointment signals HITIQ's commitment to expanding its global presence and market share. HITIQ strengthened its financial position during the quarter with the extension of its existing Convertible Note facility with its major shareholder, Harmil Angel Investments, the private investment entity of Adam McDougall. The extension increases the maximum subscription amount by $3 million, bringing the total facility to $4.6 million. The additional funds raised will be instrumental in supporting HITIQ's operational and strategic initiatives, including expanding production and manufacturing capabilities, increasing sales and marketing efforts, and accelerating global commercialisation activities.

The company had cash reserves of A$668k as at 31st December 2024. The company has a further A$500,000 available to draw on its convertible note facility, in addition to access to an R&D funding facility.

HITIQ's achievements during the December 2024 quarter reflect the Company's ongoing commitment to innovation, strategic growth, and operational excellence. The extension of the Premier League partnership, the strengthening of its leadership team, and the additional funding secured provide a robust foundation for continued success as HITIQ builds its global presence in concussion management and sports health technologies.